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balladeer enclosing an aqueous space.
When lipids are suspended in an excess
of aqueous solution, they spontaneously
give rise to a population of vesicles,
which may range in size from tens of
nanometers to tens of microns in diam-
eter; the lipid layers always encapsulate
an aqueous phase. They can be con-
structed so that they entrap materials
both within their aqueous compartment
and within the membrane. Depending
on the size and number of lipid bilayers,
they are classified as multilamellar large
vesicle or small unilamellar vesicle.
There are also giant vesicles. Bangham
and his co-workers1,2 have conducted a
physical study of liposomes.
Phospholipids and stabilizing lipids are
the main ingredients needed to form
stable liposomes structures, such as cho-
lesterol or ergosterol. Cholesterol
decreases permeability of the lipid
bilayers to the solutes. A charged
amphiphile produces electrostatic repul-
sion between any two charged bilayers
on either side of an aqueous channel.
This can greatly increase the volume of
the entrapped aqueous solution and
hence, the absolute amount of
entrapped solute. In addition, the pres-
ence of a charged component will con-
fer a positive or negative charge on the
surface of liposomes. The liposomes are
very similar to the natural membrane, in
terms of the membrane fusion, ion-
transport, membrane permeability, etc.
They are also capable of delivering
drugs, proteins, enzymes, and genetic
materials to living cells. In addition,
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ABSTRACT
Initially, the use of liposomes was mainly
confined to model membrane systems,
however, recently their use as vehicles
for transfer of genetic and other materi-
als into cells in cultures or for drug
delivery to desired cellular and subcellu-
lar sites in a living system has been the
subject of discussion. Liposomes can
vary widely in size, chemical composi-
tion, and surface characteristics; they can
accommodate a remarkable array of
pharmacologically active substances,
including antitumor and antimicrobial
drugs, enzymes, hormones, and vaccines.
Currently, specialized liposomes are pre-
pared for site-specific delivery, which
has led to considerable interest in the
possibility of therapeutic use of lipo-
somes. This paper describes different
methods for modifying liposomal sur-
faces, so that these modified liposomes
can be used as efficient macrophage spe-
cific drug carriers. Until drug specificity
is achieved, liposomes, despite their limi-
tations, will play an important role in
optimizing drug action.
INTRODUCTION
As drug delivery-vehicles, liposomes are
artificial phospholipid microcapsules
where lipids are arranged in a concentric
Basu-vol5no1  3/7/05  7:23 PM  Page 221
Vol. 5, No. 1, 2005 • The Journal of Applied Research222
they can serve as an ideal delivery sys-
tem in medicine, pharmacology, genetic
engineering, and cosmetics, as well as
the food industry.3-5
Drug targeting using liposomes or
any other particular drug carriers have
two major problems that have not been
adequately dealt with. Firstly, other than
those having a discontinuous endothelial
lining to their capillaries (eg, liver and
spleen), these carriers cannot escape
from the circulation to tissues because
of their size. The second problem con-
cerns the body’s immune system recog-
nizing liposomes as foreign particles and
their subsequent removal by phagocytic
cells of the tissues of the reticuloen-
dothelial system.
Despite these problems, liposomes
have been successfully exploited using
improved techniques in the treatment of
bacterial or parasitic infections of
macrophages, and systemic fungal infec-
tions. They have also been used in the
preparation of vaccines and in the detec-
tion of cancer. In the United States,
human trials have been conducted on
the use of liposomes for the diagnosis of
various cancers, and liposomes contain-
ing antibiotics for the treatment of infec-
tions in cancer patients.
The purpose of this review is to
focus on liposomal delivery systems,
both classical and modified, that deliver
antileishmanial drugs, increase efficacy,
and reduce drug toxicity. Drug toxicity is
a common adverse effect of antileishma-
nial agents. Antimonials, although noto-
rious for their toxic effects, remain as
the main combating force even now,
although current clinical reports indicate
that a large proportion of cases of leish-
maniasis (15%-25%) are becoming
unresponsive to antimonial treatment.6
The human protozoal pathogen
Leishmania donovani is the causative
agent for visceral leishmaniasis (kala-
azar), a fatal disease that is endemic in
parts of the tropical world. For leishma-
niasis, the target cells are the
macrophages of reticuloendothelial ori-
gin. Hence, a liposomal delivery system
has to be designed in such a way that
they are easily recognized by
macrophages, because of active target-
ing. Although a considerable amount of
work has been done on passive targeting
to the reticuloendothelial system, not
much is known about the active target-
ing to specific subsets of circulating
blood cells or to the vascular endotheli-
um. Thus, efficient delivery systems suit-
able for site-specific delivery are being
sought.
Designing of Liposomes as Carriers for
Site-Specific Delivery 
The idea of specific targeting was devel-
oped by Paul Ehrlich, who proposed
treatment of infectious diseases with a
“magic bullet”. According to him, this is
a toxin bound to a molecule with a high
affinity for a specific site. The combina-
tion could result in the destruction of
the target cell without affecting the host.
For site-specific targeting, liposomes in
combination with the therapy are direct-
ed to target sites and attach to the sur-
face to alter the normal distribution in
vivo. An ideal target would be a cell or
tissue that expresses a unique receptor
on its surface. It is, therefore, important
to identify such receptors on target cells.
A receptor is a protein molecule that
mediates the internalization of legends
via a process called receptor-mediated
endocytosis. A large variety of molecules
like antibodies, oligosaccharides, lectins,
hormones, and nucleic acid have been
used as the ligands for targeting lipo-
somes,7 but the major drawback of lipo-
some targeting is their rapid
accumulation by the fixed macrophages
of reticuloendothelial system (RES). As
such, liposomes have been designed that
circulate longer to bypass RES.8-10 With
antileishmanial therapy, the rapid accu-
mulation of liposomes in the RES seems
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to be an added advantage, since leishma-
niasis is a disease primarily associated
with the fixed macrophages of RES.
Efforts have been made to promote a
higher uptake of liposomes by the RES
through modifying liposomal surface
and by incorporating or grafting various
ligands onto the liposomal surface, so
that they are easily recognized by the
various receptors located on the
macrophages.
Glycolipid/Glycosides Bearing
Liposomes 
The liposomes are taken up nonspecifi-
cally by the RES, however, the uptake
can be increased by proper modification
of the liposomal surface or liposomal
composition. Surolia et al11 incorporated
glycolipids of varying terminal sugars
into the liposomes and showed that
these glycolipid-bearing liposomes could
be used as efficient ligands for specific
receptors on the target cells. These spe-
cific receptors recognized only the ter-
minal sugar of the glycolipid chain. The
two major cell types of the liver, hepato-
cytes and macrophages, possess distinct-
ly different receptors for galactose and
mannose, respectively.12-13 The glycolipid
orientation and the density of glycolipid
residue on the liposomal surface, chain
length of the oligosaccharide, and the
phase transition temperature (Tc) are
the parameters that dictate the nature of
binding between liposomes and cells.14
Moreover, the presence of lectin-
like molecules on the surface of hepato-
cytes and kupffer cells has also been
reported. These receptors recognize the
terminal galactose, glucose, mannose- or
fucose-containing glycosides, and thus
can be directed to different liver cell
types. A galactose terminating glycopro-
tein, asialofetuin, has been incorporated
into liposomes to direct the liposomes
towards the hepatocytes,15 however, the
major disadvantage of using the protein
as a ligand/marker stems from the fact
that the antibody responses may be
elicited against that protein. So the gly-
colipid/glycosides replaced glycoproteins
as the surface marker of liposomes.
These glycolipid/glycoside-bearing lipo-
somes can be targeted to different cell-
types of liver more efficiently. The
glycolipid should be incorporated so
that its oligosaccharide portion remains
at a high density on the surface of lipo-
somes. After intravenous injection of
such liposomes, rapid uptake by liver
took place primarily through the endo-
cytotic-process mediated by the galac-
tose receptor. Among the different
glycoside residues artificially grafted on
the liposomal surface and tested with
respect to their uptake by various
organs, the grafting of galactoside and
mannoside on the liposome surface
increased liposome uptake by the liver.
The determining factors for the uptake
of glycosylated liposomes by the liver
include the anomeric form and the den-
sity of the glycoside residues on the sur-
face of the liposomes. When plant
glycosides, with glucose as end sugars,
are incorporated into the liposomes for
targeting purposes, the glycoside-bearing
liposomes were taken up mainly by the
nonparenchymal cells, and uptake was
very specific for glucose, although inde-
pendent of various anomeric forms of
glucose.16-17
Specific receptors were observed on
the non-parenchymal or Kupffer’s cell
that recognized the terminal mannose
residue of glycoside bearing liposomes.18
The enhancing effect of cetylmannoside
on the targeting of liposomes to kupffer
cells in rats was reported earlier,19 but
according to a recent report, the uptake
by cetylmannoside was complement
receptor-mediated and not mannose
receptor-mediated.20 The presence of
aminomannose receptors on the lungs
could enable the liposomes to be direct-
ed towards lungs, and the presence of
mannose receptor on the glial cell of the
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brain could direct the liposomes through
the blood-brain barrier.21 The experi-
mental evidence on the efficacy of glyco-
sylated liposomes in targeting the
specific cell types of the liver prompted
several researchers to try to find out
whether the drugs or therapeutic sub-
stances entrapped in these liposomes
could be effective in reversing the dis-
eased condition of liver.
Antibody/Peptide-Coated Liposomes 
Targeting of various tissues or cells can
be achieved by using an antibody or
peptide-coated liposomes. As a result of
hybridoma technology, it is now possible
to obtain a monoclonal antibody for
each cell surface protein. The coupling
of such antibodies on the liposomal sur-
face would preserve the specificity of
the antibody, and the antibody-mediated
binding of liposome to the target cells
could deliver the liposomal contents into
those cells. These antibody-coated lipo-
somes are now used to deliver drugs or
other materials to specific cells or tissues
(eg, dideoxycytidine triphosphate to
human monocyte/macrophage22 doxoru-
bicin against lung cancer in mice,23 and
chloroquine to P. berghei infected
mice).24 The major drawback of such
liposomes in vivo is their rapid removal
by the RES. As the presence of Fc
receptors on the cell surfaces of RES
could increase this removal, the use of
F(ab)2 portion of the antibody was  rec-
ommended for coating the liposomal
surface for this specific purpose. The
binding to lymphocytes was three times
greater when the liposomes were pre-
pared with F(ab’’)2 fragments than with
the whole antibody, and as expected, the
binding was almost absent using the
monovalent F(ab’’) fragments. Heath,
Fraley, and Papahadjopoulos26 reported
that the cell specificity obtained by con-
jugation of F(ab’’)2 was vesicle surface
specificity. The binding of liposomes to
erythrocytes in whole blood or in vivo
increased considerably (by at least 20
times) by covalently attaching anti-ery-
throcyte F(ab’’)2 to their surface.
27
Huang, Huang and Kennel29 covalently
coupled monoclonal antibodies with
fatty acids and in vitro liposome target-
ing. Cell-specific drug transfer from lipo-
somes bearing monoclonal antibodies
was already reported.30
A large number of works have been
published on the peptide-coated lipo-
somes and their interactions with vari-
ous cells and possible applications in
chemotherapy. Several macrophage acti-
vating peptides (eg, tuftstin, N-f-Met-
Leu-Phe, N-f Met-Leu-Phe-Phe) were
also reported for targeting purposes.31-34
The tuftsin-bearing liposomes were test-
ed in vitro and their possible chemother-
apeutic role was later studied.35,36
Routes of Administration of Liposomal
Delivery System
The in vivo applicability of liposomal
delivery system depends on its routes of
administration, oral, intravenous, subcu-
taneous, dermal, transdermal, intraperi-
toneal, intramuscular or inhalation
through the bronchial track. All these
pathways have specific characteristics
and limitations. The liposomes, when
administered orally, can survive stomach
digestion, but are lysed by the lipolytic
enzymes in the intestine. It has been
shown that they can protect the
entrapped materials from such degrada-
tion and hence, this route is used for
liposomes in oral vaccination. When
injected intravenously, liposomes are
rapidly cleared from the blood and
absorbed mainly by the phagocyte cells
of the reticuloendothelial system.
Liposomes injected through subcuta-
neous, transdermal or intramuscular
routes may remain in the in circulation
longer. Thus, it may act as a depot of
drugs and facilitate the slow release of
the entrapped materials from the vesi-
cles. One report indicated the supremacy
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of the subcutaneous route over other
routes.37
Pharmacodynamics of Liposome
Encapsulated Drugs
The pharmacokinetic behavior of lipo-
some-encapsulated drugs was studied by
several researchers.38,39 They discovered
that in vivo behavior (eg, the release
characteristics of the encapsulated drug)
is dependent on the properties of the
liposomes. The specificity of the drug
release depends on the quality and com-
position of the liposomes, which increase
the efficiency of drug release to the tar-
get cells.40 Encapsulation of the drug
into the liposomes, creates a shield on
the drug and thus the rate of metabo-
lism of these drugs is less than the free
drugs. Mauk et al41 showed that SUVs
can stay in the system after a subcuta-
neous injection for up to 600 hours.
In summary, encapsulated drugs
tend to demonstrate the following phar-
macodynamic properties: retardation of
drug clearance from circulation; high
drug storage in different RES tissues;
longer drug retention in various tissues;
and retardation in the rate of drug
metabolism and elimination.
Application in Chemotherapy: As
Carrier of Antileishmanial Agent
The protozoal pathogen Leishmania
donovani is the causative agent of vis-
ceral leishmaniasis (kala-azar). It has a
digenic life cycle. The flagellated pro-
mastigotes or the vector forms are con-
verted to the aflagellated amastigotes,
which reside and multiply within the
host cell (ie, macrophages of the liver
and spleen). When injected into the
blood stream, the superior efficacy of a
liposomal drug compared to a free drug
is mainly due to the accumulation of
liposomes in the liver and spleen. For
leishmaniasis therapy, the antimonials
are the drugs of choice, although notori-
ous for their toxic effects. The superior
efficacy of various antimonial drugs like
meglumine antimoniate or sodium sti-
bogluconate in liposomal form has been
compared to their respective free
drugs.42,43 In addition to visceral leishma-
niasis, New, Chance, and Heath44 extend-
ed their observations to show that
liposomes also enhance the activity of
sodium stibogluconate against experi-
mental cutaneous leishmaniasis, when
the parasites are located in the
macrophages in peripheral tissues, rather
Figure 1. Coupling of p-aminophenyl-a-D-mannoside with PE liposomes.
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than in the liver. Recently a classical
drug urea-stibamine was used in the
liposomal and in the mannose-grafted
liposomal forms to combat experimental
leishmaniasis in a hamster model. The
mannose-grafted liposomal form was
judged more efficient in transporting the
drug to the specific site;45 the efficacy
and toxicity of this drug have also been
critically analyzed and compared using
different sugar bearing liposomes.
Mannose-bearing liposomes have
proved more efficient in the transporta-
tion of drugs compared to those bearing
glucose or non-bearing liposomes (ordi-
nary liposomes) (Figure 1). Toxicity
studies also show no apparent drug toxi-
city in either of the two sugar bearing
liposomal forms. Very recently, Tampon
et al,46 in an in vitro approach, used the
Figure 2. A). Asiaticoside. B). Acaciaside.
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negatively charged lipid phos-
phatidylserine-liposome-entrapped anti-
mony to improve targeting to L. chagasi
infected macrophages through the inter-
action with the scavenger receptor of
macrophages. Besides the antimonials,
imidines, aminoquinolines or various
antibiotics, they are also being used for
the treatment of both visceral and cuta-
neous leishmaniasis. This group of drugs
has gained their importance because
most of the Leishmania parasites are
antimony resistant and the number of
new resistant cases is alarming to scien-
tists worldwide.
Second line drugs, (eg, ampho-
tericin-B, pentamidine isethinonate) are
too toxic for use as first-line therapy on
a large scale. Increasing the dosage of
antimony may at least temporarily over-
come parasite resistance, but at the same
time would increase the risk of serious
side effects. Therefore, new drugs or
delivery systems have been sought. Thus,
amphotericin-B (in the liposomal form),
despite its limitations, was tried to com-
bat leishmaniasis both in model disease47
and also in clinics by several groups of
researchers.48 Croft et al49 used liposomal
amp-B (AmBisome) in the treatment of
patients suffering from multidrug resist-
ance visceral leishmaniasis. In a non-
empirical approach to antileishmanial
drug design and delivery, lipoprotein
mediated antileishmanial chemotherapy
was studied.50The idea of utilization of a
specific receptor by low density lipopro-
tein (LDL) and acetylated LDL on
Leishmania infected macrophages was
exploited in vitro to selectively deliver
the anti-leishmanial drug adriamycin.
One of the 8-aminoquinoline groups
of compounds, primaquine, known for its
antimalarial effect, had a limited leish-
manicidal effect.51 Whether the efficacy
of primaquine could be increased a rea-
sonable extent using an appropriate
delivery system, remains an open ques-
tion. The effectiveness of these drugs
could be increased significantly by prop-
Figure 3. Survival of hamsters after treatment with free asiaticoside.
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er manipulation of the liposomal com-
position or modification of the liposos-
mal surface by incorporating or grafting
different ligands, appropriate for the
receptors on the host-cell surface.17,35,45
Lately, it was demonstrated that pri-
maquine encapsulated in peptide-graft-
ed liposomes or f Met-Leu-Phe-grafted
liposomes was more effective in lower-
ing the spleen parasite load in experi-
mental leishmaniasis compared with its
efficacy in either the free form or encap-
sulated in ungrafted liposomes.52
Treatment of visceral leishmaniasis with
sterically stabilized liposomes containing
camptothecin  was  reported, but nor-
mochromic anemia and neutropenia
developed as side effects.53
Very recently, different sugar-coated
liposomal delivery systems were
designed, either by incorporating plant
glycosides or by grafting synthetic glyco-
sides, and their specificity toward
macrophages was tested in vitro using
appropriate inhibitors.17 The neoglycosy-
lated liposomes were also used as effi-
cient ligands for the estimation of
specific sugar receptor status of
macrophages in heath and in experimen-
tal leishmaniasis.54 Some plant glycosides
(eg, amarogentin isolated from Indian
Medicinal Plant, Swertia chirata,55 and
Bacopasaponin C isolated from Indian
Medicinal Plant, Bacopa monniera56)
were reported  to have antileishmanial
properties. Thus, after incorporation in
the liposomes, they serve two purposes,
1) the end sugar of the hydrophilic sugar
chain, which sticks out of the liposomal
surface, acts as ligands for appropriate
receptors on the macrophage surface;
and (2) because of their leishmanicidal
properties, they also act as an indigenous
antileishmanial drug. Hence, these atypi-
Figure 4. Dose-dependent reduction of parasite burden in spleen of hamsters treated with asiati-
coside.
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cal plant glycosides are appropriate for
site-specific delivery to combat leishma-
niasis, and because of their indigenous
and nontoxic nature, they are expected
to be useful in clinical applications.
Two indigenous glycosides, one hav-
ing glucose as an end sugar in the
hydrophilic sugar chain (eg, acaciaside)
(Figure 2A) and the other having rham-
nose as an end sugar with no tissue
specificity but having leishmanicidal
property (eg, asiaticoside) (Figure 2B),
were incorporated together into the
liposomes in definite molar proportion
to combat experimental leishmaniasis in
animal models. The multiple dose
response curve of free asiaticoside on
the survival of hamsters is shown in
Figure 3. The dose-dependent reduction
of parasite burden in the spleens of
hamsters when treated with asiaticoside
alone is shown in Figure 4. Thus, the
optimum dose for chemotherapy was 4
mg/kg of body weight. The host cell via-
bility at varying concentrations of asiati-
coside is shown in Figure 5. In the
treated group, at the 500 µg/mL concen-
tration, the drug demonstrated 97% via-
bility, compared to untreated controls,
where the drug demonstrated 96% via-
bility. After chemotherapy, both acacia-
side- and asiaticoside-incorporated
liposomes were more efficient in lower-
ing the spleen parasite load compared to
asiaticoside incorporated liposomes or
to free asiaticoside used as an antileish-
manial agent (Table 1). Toxicity studies
involving the levels of normal liver func-
tion enzymes also indicated the appar-
ent nontoxic nature of the drug (ie,
asiaticoside) when co-incorporated with
acaciaside in the liposomes (Table 2).
The non-antimonial classical drugs,
pentamidine isethionate, and their ana-
logues were also examined in vitro for
antileishmanial activities.57,58 When
encapsulated in mannose bearing lipo-
somes, therapeutic efficacy and resultant
toxicity were critically analyzed.59
Moreover, hamycin, a polyene antibiotic,
was examined in our laboratory for
antileishmanial activity. When tested in
vivo against experimental leishmaniasis,
in a hamster model, the liposomal
Figure 5. Trypan blue exclusion test to assess host cell viability against asiaticoside. 
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hamycin and mannose-bearing liposo-
mal hamycin were more potent than
regular hamycin; the mannose bearing
liposomal hamycin was the most effec-
tive in reducing the spleen parasite load.
Toxicity of the drug was reduced in the
liposomal forms, as determined by
hemoglobin levels and the level of spe-
cific enzymes related to normal liver
function. Toxicity was reduced reduced
when sterol-rich liposomes were used as
a delivery system.60
Cationic liposomes have been used
to deliver DNA to target cells. Using an
in vitro approach, it was demonstrated
that cationic liposome-encapsulated
antisense oligonucleotides, complimen-
tary to the Leishmania universal miniex-
on sequence, mediate efficient killing of
intracellular Leishmania.61 Prior to that
study, a significant leishmanicidal effect
was reported using phosphorothioate
oligonucleotides encapsulated in maley-
ated albumin coated liposomes.62
Enhanced activity of antisense phospho-
rothioate oligos against Leishmania
amastigotes was reported later.63 An
augmented uptake of oligo, ribunuclease
activation, and efficient target interven-
tion were also observed under altered
growth conditions. Recently, an anti-
sense oligonucleotide, targeted to the
parasite b-tubulin gene and encapsulat-
ed in cationic liposomes, was used to test
its antileishmanial activity in vitro.
Cationic liposomes containing dioleyl
trimethyl ammonium propane
(DOTAP) had higher antileishmanial
activity (88% at 4 µM oligonucleotide)
compared to other liposomes with
stearyl amine (SA) and cetyl trimethyl
ammonium bromide (CTAB) as cations.
This work also showed that antisense
oligonucleotides targeted to the b-tubu-
lin gene of Leishmania donovani inhibit
b-tubulin synthesis, which stop intracel-
lular parasites from multiplying.64
Immunoliposomes have also been
developed for combating experimental
leishmaniasis. Characterization of
Leishmania donovani antigens encapsu-
lated in liposomes induced protective
immunity in BALB/c mice.65,66 With
maximum induction by positively
charged liposomes, followed by neutral
liposomes and lastly by the negatively
charged liposomes, the extent of protec-
tion induced by the same antigens var-
Table 1. Effect of Asiaticoside on a 30-day Infected Hamster Model of 
L. donovani (AG83 strain)*
Treatment Liver wt (gm) Parasite load in % Suppression of
(mean ± SD) spleen (X10-9) parasite load in 
spleen
No drug (control) 4.05 ± 0.25 2.9 ± 0.9 —
Free drug 3.50 ± 0.20 1.5 ± 0.5 47
Liposomal drug 2.35 ± 0.30 0.6 ± 0.3 62
Acaciaside-coated 2.05 ± 0.35 0.2 ± 0.8 92
liposomal drug
*The reduction of parasite load, by administration of empty liposomes, both regular and acaciaside-coated, was
approximately 12% to 14%. Results are shown as Mean ± SD (n = 3).
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ied depending on the charge of the vesi-
cles. Effective immunization against
cutaneous leishmaniasis was noted when
defined membrane antigens were recon-
stituted into liposomes.67 Liposomes
coated with neoglycolipids constructed
with mannopentose and dipalmitoyl
phosphatidyl ethanolamine (Man5-
DPPE) induced cellular immunity
against antigens encapsulated in the
liposomes (using L. major infection in
susceptible balb/c mice).68 These results
indicate that Man5-DPPE-coated lipo-
some-encapsulated antigen could serve
as a vaccine to trigger protection against
infection. Several immunomodulators
have been studied for active or passive
targeting. Active targeting of muramyl
dipeptide (MDP) to macrophages was
studied by conjugation with the neogly-
coprotein, mannosyl serum albumin
(mannose-HSA), using visceral leishma-
niasis as the model disease.69
Conjugation did not decrease the affini-
ty of the neoglycoprotein for
macrophage mannose receptor.
Mannose-HSA-MDP was 50 times more
efficient than free MDP in inhibiting the
growth of Leishmania donovani inside
the peritoneal macrophages. Kole et al70
in attempting active targeting noticed a
synergistic effect of interferon-gamma
and doxorubicin, when incorporated in
mannosylated liposomes for therapy of
experimental visceral leishmaniasis. But,
a similar synergistic effect in natural tar-
geting of glucantine and liposome-
encapsulated muramyl dipeptide analog
was reported earlier.71Targeting of
immunostimulatory DNA, encapsulated
in mannose-grafted liposomes reported
to cure experimental visceral leishmani-
asis through nitric oxide up regulation
and T cell activation.72 Liposomes bear-
ing surface-attached antibodies, raised
against parasite-specific antigen, were a
better approach in combating the dis-
ease in a more precise manner.73
Chemotherapy: Experimental to Clinical
Although miltefosine is being used for
treating visceral leishmaniasis in India,74
no report of ligand directed active drug
targeting in the field of leishmaniasis in
humans has been reported. But, cases of
natural targeting to macrophages involv-
ing some familiar antileishmanial drugs,
(eg, AmBisome) are very common.75,76
Table 2. Specific Enzyme Level in Sera of Hamsters Undergoing Experimental Leishmaniasis*
Enzyme activity
Groups
Alkaline phosphates† SGPT‡
Normal 13.4 ± 2.1 76.0 ± 12.0
Infected control 16.9 ± 2.7 104.1 ± 19.1
Free drug 14.2 ± 1.0 99.1 ± 24.7
Liposomal asiaticoside 13.9 ± 1.0 78.8 ± 28.8
Acaciaside-coated liposomal drug 13.9 ± 2.1 76.6 ± 17.1
*Results are shown as Mean ± SD (n = 4).
†µmol of p-nitrophenol released/min/dL of serum.
‡µmol of sodium pyruvate/min/L of serum.
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Successful treatment with liposomal
amphotericin B for antimony resistant
cutaneous leishmaniasis,77 visceral leish-
maniasis infected with HIV,78 and
AIDS79 were also reported. Apparently,
successful treatment of post kala-azar
dermal leishmaniasis (PKDL) with lipo-
somal amphotericin B has been report-
ed.80 Sundar and Murray81 were
successful in curing antimony unrespon-
sive Indian Visceral leishmaniasis with
amphotericin B lipid complex. Thicker
et al82 conducted a randomised dose
finding study to compare three treat-
ment regimens with AmBisome for vis-
ceral leishmaniasis in India. Bodhe et
al83 introduced a 10-day courses of L-
amp B-LRC (Bombay), a new liposomal
amphotericin B, to treat visceral leish-
maniasis in India. Unfortunately, no
other formulations proposed so far have
the potential to be used as widely as the
amphotericin B in the liposomal form.
Thus, new drugs and delivery systems
need to be developed to combat epi-
demics on leishmaniasis.
EXPERT OPINION AND 
CONCLUSION
Due to their biodegradability, biocom-
patibility, non-toxic, and non-immuno-
genic nature, ease of administration, and
capability of long-term sustained
release, liposomes have shown great
promise in the delivery of therapeutic
substances. But despite extensive
research, liposome-mediated therapy in
humans is not a reality. However, at
present with a much clearer understand-
ing of the limitations of liposome tech-
nologies, as well as a better technical
understanding of designing and manu-
facturing these phospholipid based vesi-
cles, companies are conducting an
impressive number of drug trials in
humans. But to date, liposomes have
been most effective against cancer and
to some extent against fungal and para-
sitic infections.
Moreover, the time has come when
the efficacy of liposomes needs to be
tested against other classic drug carriers
(eg, neoglycoproteins, niosomes, etc).
The biggest challenge will come from
polymeric delivery vehicles (eg, micros-
pheres and nanoparticles), which are
made of cost effective natural or syn-
thetic biodegradable polymers. Because
of their small size and highly stable
nature, the use of nanoparticles as effec-
tive drug carriers has been explored in
experimental leishmaniasis using a series
of antileishmanial compounds.84,85 The
efficacy in reducing the spleen parasite
load, as well as reducing the hepatotoxi-
city and renal toxicity compared to free
drugs or drugs incorporated in other
delivery vesicles varied according to the
delivery vesicles used. Best efficacy was
shown by nanoparticles, followed by nio-
somes, liposomes, microspheres and free
drug.
Thus, it is obvious that, the feasibili-
ty of the use of nanoparticles in clinics is
much better than that of liposomes
and/or any other existing drug delivery
vesicles. However, the future role of
liposomes in newly designed delivery
systems has yet to be determined.
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